Seth Alpna sold $28K of KROS
Seth Alpna sold 2,625 shares of Keros Therapeutics, Inc. (KROS) at $10.72 on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This disclosure provides a datapoint on insider activity but does not introduce new company fundamentals (no guidance, trial, or deal information).
Market read
Traders may briefly reassess sentiment around KROS insider activity, but the 10b5-1 structure and small value suggest limited trading edge.
What to watch
Check for any concurrent insider buys/sales by other directors/officers and whether the company has upcoming clinical or financing catalysts not mentioned here.
Background
SEC Form 4 reports insider transactions; 10b5-1 plans are pre-set trading schedules intended to reduce timing-based trading concerns.
Ticker impact
Director Seth Alpna sold 2,625 Keros Therapeutics shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Limited/short-lived impact; any reaction likely fades unless accompanied by other negative catalysts.
The filing is a routine 10b5-1 sale with a modest dollar value ($28.14K) and no accompanying operational or clinical news.
Market effects
No direct sector read-through; this is company-specific insider disclosure without new clinical/regulatory information.
None.
None.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.
Key entities
- issuerKeros Therapeutics, Inc.
Subject of the Form 4 insider sale disclosed by director Seth Alpna.
- insiderSeth Alpna
Director who executed an open-market sale of 2,625 shares under a 10b5-1 plan.